Global Cytotoxic Drugs Market Size, Share and Trends Analysis Report, By Drug Class (Alkylating, Antimetabolites, Antitumor Antibiotics, Plant Alkaloids, and Others), By Application (Lung Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, and Others) Forecast Period (2022-2028)

The global cytotoxic drugs market is anticipated to grow at a significant CAGR of 1.4% during the forecast period (2022-2028). Anticancer medications known as cytotoxic drugs are primarily used to treat cancer. Cancer cell’s proliferation is slowed by these medications, that block the process of cell division in cancer cells. Cytotoxic medicines aid in the prevention of cancer metastasis and the alleviation of cancer symptoms. These medications are injected into the bloodstream and quickly spread throughout the body. Increased adoption of cytotoxic chemotherapy for the treatment of breast cancer; rising lung cancer prevalence; growing awareness of the importance of early cancer treatment; rising demand for alkylating agents and antitumor antibiotics for the treatment of various cancers in developed countries; and rising government initiatives to raise awareness and funds for the disease are all the driving factors boostingthe growth of the global cytotoxin market.

 

Some major players in the market include Pfizer Inc. Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Johnson & Johnson Services, Inc. Bristol Myers Squibb Co., and others. The market players are serving significantly in the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, in order to stay competitive in the market. For instance-

 

• In October 2021, NanoString Technologies, Inc. had launchedthe nCounter ADC Development Panel, a customized gene expression instrument for use in the rapidly increasing field of Antibody Drug Conjugates (ADCs). This novel nCounter ADC Development Panel will aid in the development of medications that can distinguish between healthy and cancer tissues using cytotoxic chemicals’ cell-killing powers, reducing side effects on healthy tissues and cells.
• In May 2021, Zydus Cadila had launchedglobe’s first biosimilar version of trastuzumab emtansine, an antibody-drug combination that not only inhibits cancer cell development (trastuzumab) but also delivers a cytotoxic agent to the cancer cell, assisting in its destruction.
• In April 2020, Roche Holding AGhad launched atezolizumab, a cytotoxic medication for the treatment of metastatic triple-negative breast cancer (TNBC) in India. This medication is used as a first-line treatment for TNBC patients when coupled with nab-Paclitaxel.
• In January 2020, Pfizer has introduced cytotoxic medications in the USat a far lower price than the original manufacturers in order to expand the indication to include the treatment of epithelial ovarian and primary peritoneal cancer.
• In May 2019, Teva Pharmaceuticals had developed a generic version of the cytotoxic medicine Tarceva 1 (erlotinib) tablets, that is a kinase inhibitor recommended for the treatment of patients with non-small cell lung cancer (NSCLC).

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Class
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

· Competitive Landscape– Pfizer Inc. Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Johnson & Johnson Services, Inc. Bristol Myers Squibb Co., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cytotoxic Drugs Market Report by Segment

By Drug Class

• Alkylating
• Antimetabolites
• Antitumor Antibiotics
• Plant Alkaloids
• Others

By Application

• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer
• Others

Global Cytotoxic Drugs Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa